LICOPENO E MARCADORES METABÓLICOS: UMA REVISÃO NARRATIVA.

Objective: to define the action of lycopene under CT, HDL, LDL and TG and to analyze which sufficient dosages have a positive effect on metabolic markers. Methodology: The investigation was based on the effect of products containing lycopene and its effect on serum metabolic markers of total cholesterol, LDL, HDL and triglycerides. For analysis of in vivo studies, studies that met intervention criteria with controlled design, diet or manipulated controlled by crossed or parallel placebo, randomized clinical trial with standardized dosage of lycopene in the treatment and control group and intervention 2= weeks that included total cholesterol, HDL, LDL, and triglycerides were included.. Results: It was seen that lycopene plays an important role on metabolic markers, due to its ability to reduce the mechanism of HMG-Coa reductase, decreasing the synthesis of cholesterol and its antioxidant capacity under LDL. Lycopene also modulated the activity of PPAR and LXR, modulating the action of ABCA1, Apoa1 and caveolins, improving HDL synthesis and cholesterol efflux. Dosages with a positive cholesterol effect vary, but are around 26.5 mg of lycopene per day, reported in in vivo studies with cholesterol supplementation. Conclusion: The review suggests the efficacy of lycopene in reducing metabolic markers, thus reducing the risk of atherosclerotic diseases. [ABSTRACT FROM AUTHOR]